Simeglutide: From Lizard Venom to Global Medicine King, the Path to Sealing the Gods of a Generation of Divine Medicines

In 2004, smeglutide was first clinically tested in patients with diabetes, with significant effects

2017: FDA approved for treatment of type 2 diabetes

2021: Unexpectedly discovered its powerful weight loss effect, approved for use in obesity treatment

2024: Added indications for chronic kidney disease, becoming the first GLP-1 class drug with renal protective effects

Key clinical data Type 2 diabetes: improvement of blood glucose control

Obesity: Significant weight loss effect, with an average weight loss of 15%, and 33% of patients losing over 20%

Cardiovascular protection: reduced risk of cardiovascular events=chronic kidney disease: huge market potential for renal protection. 2021: approved for weight loss indication, with annual sales of approximately $2 billion

2022: Sales increase by 70% to reach 3.4 billion US dollars

2023: Sales increase by 110% to reach $7.2 billion

2024: Sales exceed $17 billion, a year-on-year increase of 136%

More potential of semaglutide for anti-aging? Preliminary research suggests that it may delay cellular aging

Neuroprotection? Potential applications in Alzheimer's disease and Parkinson's disease

Metabolic syndrome? Precautions for comprehensive treatment of obesity, hyperlipidemia, and hypertension

1. Obtain through legitimate channels: Please obtain through hospital prescriptions and do not trust online purchasing agents

2. Dose adjustment: The initial dose is usually low and gradually increases to the effective dose

3. Possible side effects: Gastrointestinal reactions such as nausea and diarrhea, which usually subside within a few weeks

4. Applicable population: Obese individuals with BMI ≥ 27 or BMI ≥ 24 and related complications

5. Taboo population: Patients with a family history of medullary thyroid cancer or MEN2 syndrome are contraindicated